Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001125 · ClinicalTrials.gov registry record · Phase 1
Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox
A Phase 1 study of HIV Infections and Chickenpox, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT00001125: Completed Phase 1 study of HIV Infections and Chickenpox, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00001125 is a Phase 1 study of HIV Infections and Chickenpox that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 60 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001125, a Phase 1 study of HIV Infections and Chickenpox, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see if the varicella-zoster virus (VZV) vaccine will be safe and if it can help prevent shingles in HIV-infected children who have already had chickenpox. VZV is the virus that causes chickenpox. If this virus is reactivated in the body, it can also cause shingles. Shingles is common in children with HIV who have had chickenpox, although it is usually not life-threatening. The VZV vaccine used in this study may be able to prevent HIV-positive children who have had chickenpox from developing shingles.
Conditions Studied
Interventions
- BIOLOGICAL Varicella Virus Vaccine (Live)
Study Locations (20)
New York
- Nyu Ny Nichd Crs - New York
- Cornell Univ., Div. of Ped. Infectious Diseases & Immunology - New York
- Columbia IMPAACT CRS - New York
- Harlem Hosp. Ctr. NY NICHD CRS - New York
- Strong Memorial Hospital Rochester NY NICHD CRS - Rochester
- SUNY Upstate Med. Univ., Dept. of Peds. - Syracuse
California
- Long Beach Memorial Med. Ctr., Miller Children's Hosp. - Long Beach
- Usc La Nichd Crs - Los Angeles
- UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS - Los Angeles
- Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases - Torrance
Florida
- South Florida CDTC Ft Lauderdale NICHD CRS - Fort Lauderdale
- Univ. of Florida Jacksonville NICHD CRS - Jacksonville
- Univ. of Miami Ped. Perinatal HIV/AIDS CRS - Miami
Massachusetts
- HMS - Children's Hosp. Boston, Div. of Infectious Diseases - Boston
- BMC, Div. of Ped Infectious Diseases - Boston
- Baystate Health, Baystate Med. Ctr. - Springfield
New Jersey
- Cooper Univ. Hosp. - Camden
- NJ Med. School CRS - Newark
Pennsylvania
- The Children's Hosp. of Philadelphia IMPAACT CRS - Philadelphia
- St. Christopher's Hosp. for Children - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Est. Completion | 2004-03 |
| Phase | Phase 1 |
What the finished NCT00001125 record still lists
NCT00001125 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Varicella Virus Vaccine (Live) is the first listed.
NCT00001125 names 20 study sites across 6 states, led by New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00001125 about?
NCT00001125 is a clinical study titled "Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox". The purpose of this study is to see if the varicella-zoster virus (VZV) vaccine will be safe and if it can help prevent shingles in HIV-infected children who have already had chickenpox. VZV is the virus that causes chickenpox. If this virus is reactivated in the body, it can also cause shingles. S...
What is the current status of trial NCT00001125?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. Estimated completion is 2004-03.
What conditions does trial NCT00001125 study?
This clinical trial studies the following conditions: HIV Infections, Chickenpox.
What interventions are being tested in trial NCT00001125?
The interventions under investigation include: Varicella Virus Vaccine (Live) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00001125?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001125 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001125's enrollment target sits among peer trials
60 322nd of 542 higher than 205 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors